Large
Global AR Population
1.2MM
US Patients with Aortic Regurgitation (1)
75,000
Diagnosed Annually with Mod. / Severe AR (2)
Severe Symptomatic AR (ssAR) is Undertreated
Only
26%
of ssAR patients had SAVR within 1 year (2)
Severe Symptomatic Aortic Regurgitation is a Class I Recommendation for SAVR
ssAR w/o treatment
at 1 year has
2.7x Mortality rate
Need for
Earlier AR Treatment
2-4x higher mortality rate with 6-month delay for patients with LV dilatation
“To move the needle toward better outcome, our data suggest that AVR might be considered relatively early, before LVESDi >25 mm/m2 and when LVESDi progressively increases beyond 20 mm/m2.” 3
Aortic Regurgitation Management is Changing
Mirroring the trends of Mitral Regurgitation, aortic valve repair is being considered more frequently with Aortic Regurgitation. Advancements in aortic valve repair are enabling surgeons to repair more types of AI & expand the benefits of valve repair to more patients.
Benefits of
Aortic Repair
No Life-long Anticoagulation
Lower valve related complications
<<I will add in some bullets like this>>
New Options
in Valve Repair
Aortic Ring Annulplasty is a new valve repair options that is expanding the benefits of valve repair to more patients.
Internal annuloplasty approach, similar to mitral valve repair, stabilizes the annulus and avoids the need for total root replacement and coronary reimplantation.
Updated Guidelines & Earlier Treatment
Detecting the leak / Multimodality Imaging
New repair options
Download White Paper to see how AR Management is changing
References
- Singh JP, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 1999;83:897-902
- IQVIA: HPD Report on Echocardiography for AI in US Q4’18-Q3’19 – Segmented by indication
- Reference: Yang, L. T., et al. (2019). "Outcomes in Chronic Hemodynamically Significant Aortic Regurgitation and Limitations of Current Guidelines." J Am Coll Cardiol.
